Taro Pharmaceuticals North America, Inc.

Taro Pharmaceutical North America, Inc.

Rao, Srinivasa

Srinivasa Rao

Avraham Yacobi

Suresh Dixit

Arthur Bailey

The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C-Calcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C-Calcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9&#x3b1;-fluoro-11&#x3b2;-hydroxy-16&#x3b1;-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

Stable liquid desoximethasone compositions with reduced oxidized impurity

The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C-Calcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C-Calcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9&#x3b1;-fluoro-11&#x3b2;-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

Growing community of inventors

Valley Stream, NY, United States of America

Srinivasa Rao